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Background and Purpose: Hepatocellular carcinoma (HCC) patients with severe cirrhosis are usually treated with supportive care 
because of their poor prognosis. However, the survival of severe cirrhotic patients has recently improved due to advanced treat-
ments. The aim of this study was to define the role of proton beam therapy for HCC patients with severe cirrhosis.
Patients and Methods: 19 HCC patients with Child-Pugh class C cirrhosis received proton beam therapy. The hepatic tumors were 
solitary in 14 patients and multiple in five, and the tumor size was 25–80 mm (median 40 mm) in maximum diameter. No patient 
had regional lymph node or distant metastasis. Total doses of 50–84 Gy (median 72 Gy) in ten to 24 fractions (median 16) were 
delivered to the tumors.
Results: Of the 19 patients, six, eight and four died of cancer, liver failure and intercurrent diseases, respectively, during the 
follow-up period of 3–63 months (median 17 months) after treatment. A remaining patient was alive with no evidence of disease 
33 months after treatment. All but one of irradiated tumors were controlled during the follow-up period. Ten patients had new 
intrahepatic tumors outside the irradiated volume. The overall and progression-free survival rates were 53% and 47% at 1 year, 
respectively, and 42% each at 2 years. Performance status and Child-Pugh score were significant prognostic factors for survival. 
Therapy-related toxicity of grade 3 or more was not observed.
Conclusion: Proton beam therapy for HCC patients with severe cirrhosis was tolerable. It may improve survival for patients with 
relatively good general condition and liver function.
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Protonentherapie bei Patienten mit Leberzellkarzinom und schwerer Zirrhose
Hintergrund und Ziel: Patienten mit Leberzellkarzinom (HCC [„hepatocellular carcinoma“]) und schwerer Zirrhose werden auf-
grund der schlechten Prognose gewöhnlich konservativ behandelt. Allerdings haben fortschrittliche Therapien in letzter Zeit zu 
einer Verbesserung der Überlebenszeit von Patienten mit schwerer Zirrhose geführt. Das Ziel der vorliegenden Studie war die 
Bestimmung der Rolle einer Protonentherapie für HCC-Patienten mit schwerer Zirrhose.
Patienten und Methodik: 19 HCC-Patienten mit Zirrhose der Child-Pugh-Klasse C wurden mit Protonenstrahlen behandelt. 14 
Patienten wiesen einzelne und fünf Patienten multiple Lebertumoren auf. Hinsichtlich der Tumorgröße variierte der maximale 
Durchmesser dabei zwischen 25 und 80 mm (durchschnittlich 40 mm). Keiner der Patienten hatte regionäre Lymphknoten- oder 
Fernmetastasen in regionären oder entfernten Lymphknoten. Die Gesamtstrahlendosis betrug 50–84 Gy (durchschnittlich 72 Gy) 
und wurde in zehn bis 24 Fraktionen (durchschnittlich 16 Fraktionen) verabreicht.
Ergebnisse: Im Nachuntersuchungszeitraum von 3–63 Monaten (durchschnittlich 17 Monate) verstarben sechs der insgesamt 
19 Patienten an Krebs, acht an Leberversagen und vier an interkurrierenden Erkrankungen. Ein Patient war 33 Monate nach der 
Behandlung ohne Krankheitszeichen am Leben. Mit einer Ausnahme wurden alle Tumoren während der Nachuntersuchung mit 
entsprechenden Kontrollen verglichen. Zehn Patienten hatten intrahepatische Tumoren, die außerhalb des bestrahlten Bereichs 
lagen. Die Gesamt- und die progressionsfreie Überlebensrate betrugen nach 1 Jahr 53% und 47% und nach 2 Jahren 42%. Der 
Performance-Status und die Child-Pugh-Bewertung waren wichtige prognostische Faktoren für das Überleben.
Schlussfolgerung: Die Protonentherapie war für Patienten mit Leberzellkarzinom und schwerer Zirrhose tolerabel. Die Behand-
lung könnte das Überleben von Patienten mit relativ gutem Allgemeinzustand und guter Leberfunktion verbessern.
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Introduction 
Currently, hepatocellular carcinoma (HCC) patients can be 
effectively treated with various modalities, i.e., surgical resec-
tion, transcatheter arterial embolization (TAE) and infusion 
chemotherapy (TAI), percutaneous ethanol injection (PEI) 
and microwave coagulation (PMC), and radiofrequency abla-
tion (RFA) [16]. However, these treatment modalities are of-
ten unsuitable for patients with severe cirrhosis because of the 
potential risk of liver failure or bleeding; furthermore, their 
prognosis is poor due to severe cirrhosis [8]. Therefore, HCC 
patients with severe cirrhosis are usually treated with pallia-
tive or supportive care [3]. 
At our institute, University of Tsukuba, Japan, proton 
beams have been employed in treatment for a variety of malig-
nancies including HCC since 1983 [4, 11, 19, 30]. Proton beam 
irradiation yields theoretically excellent dose localization to 
the target due to sharp distal fall-off of the Bragg peak com-
pared with photon irradiation, and consequently can reduce 
the irradiated volume and dose given to the hepatic paren-
chyma and digestive tract for HCC patients, while increasing 
the dose to the tumor [12, 21, 26, 28]. 
We present herein the treatment results of proton beam 
therapy for HCC patients with severe cirrhosis. 
Patients and Methods 
Patients 
Between November 1990 and January 2000, 197 HCC pa-
tients received proton beam therapy. Of these patients, 19 
had severe cirrhosis categorized as Child-Pugh class C at the 
initiation of proton beam therapy [25]. All patients were in-
operable, and TAE and TAI were contraindicated due to the 
potential risk of liver failure. PEI, PMC and RFA were un-
feasible because of bleeding tendency, large-sized tumors, or 
unfavorable tumor location. There were no other available 
treatment modalities for these patients. Exclusion criteria for 
proton beam therapy included extrahepatic metastasis, dif-
fusely infiltrated tumor, and poor general condition of the 
Eastern Cooperative Oncology Group (ECOG) performance 
status ≥ 3 [23]. 
HCCs were diagnosed histopathologically by biopsy in 
eight patients, and clinically by medical imaging; contrast-en-
hanced computed tomography (CT) or magnetic resonance 
imaging (MRI), and elevated serum α-fetoprotein (AFP) val-
ues in eleven patients. None had regional lymph node enlarge-
ment or distant metastasis. 14 and five patients were diagnosed 
clinically as stage I (T1 N0 M0) and stage II (T2 N0 M0), re-
spectively, based on the TNM classification defined by the 
International Union Against Cancer (UICC), at the time of 
proton beam irradiation [27]. 
Patient and tumor characteristics are summarized in Ta-
ble 1. Written informed consent was obtained from all patients 
before initiation of proton beam therapy. 
Proton Beam Therapy 
Metallic fiducial markers for proton beam therapy were im-
planted percutaneously into the hepatic parenchyma beside 
the tumors. Treatment planning for proton beam therapy was 
based on CT images at 5-mm intervals in the treatment posi-
tion. Clinical target volume (CTV) was defined as gross tu-
mor volume plus 5-mm margin. Planning target volume, which 
included CTV with 5-mm margin, was homogeneously set at 
the 100% dose level by utilizing the spread-out Bragg peak 
(SOBP) of proton beams (Figure 1). Multiple hepatic tumors, 
which were observed in five patients, were entirely included 
within the target volume. 
Proton beams generated by a booster synchrotron of the 
High Energy Accelerator Research Organization were de-
graded to ≤ 250 MeV for clinical use. The beams synchro-
nized with respiration were delivered through the horizontal 
or vertical port for treatment. Respiratory gating was con-
trolled by means of a strain gauge (Kyowa Electronic Instru-
ments, Tokyo, Japan) attached to the abdominal surface of the 
patients, so that proton beams were delivered to the tumors in 
expiratory phase when the tumor position was considered to 
be most stable and reproducible [13, 22]. For each treatment 
Table 1. Patient and tumor characteristics. HBV: hepatitis B virus; HCV: 
hepatitis C virus; AFP: α-fetoprotein. 
Tabelle 1. Patienten- und Tumorcharakteristika. HBV: Hepatitis-B-
Virus; HCV: Hepatitis-C-Virus; AFP: α-Fetoprotein. 
Total number of patients  19
Gender
• Male  14
• Female   5
Age (years)
• Range  51–69
• Median  61
Performance status
• 0   1
• 1  10
• 2   8
Etiology of cirrhosis
• HBV   1
• HCV  16
• Alcohol   2
Child-Pugh score
• 10   4
• 11   2
• 12   8
• 13   3
• 14   2
Number of tumors
• Solitary  14
• Multiple   5
Tumor size (mm)
• Range  25–80
• Median  40
Serum AFP value (ng/ml)
• Range  2–12,539
• Median  93Hata M, et al. Proton Beam Therapy for HCC Patients with Severe Cirrhosis
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session, the positional relationship between the center of the 
target and the fiducial markers was examined, with the pa-
tients lying in the treatment position, by the fluoroscopy unit 
attached to the treatment unit.
Fraction size was 3–5 Gy daily, 3–5 days per week; total 
doses were 50–84 Gy (median 72 Gy) in ten to 24 fractions 
(median 16). A relative biological effectiveness value of 1.0 
was utilized in accordance with data obtained from fibrosar-
coma NFSa cells [2]. Evaluation by doses of 2 Gy per fraction-
equivalent calculated using a linear-quadratic model with 
α/β ratios of 10 and 3 for early and late responding tissues re-
vealed total doses equivalent to 63–95 Gy (median 87 Gy) and 
79–109 Gy (median 107 Gy), respectively [31].
Follow-up Procedure and Evaluation Criteria 
The patients had serum AFP value measurements and ab-
dominal imaging studies (CT or MRI) approximately 1 and 2 
months after completion of proton beam therapy, respective-
ly, and then were followed at intervals of 1–3 months. Local 
responses to proton beam therapy were classified according to 
the World Health Organization (WHO) response evaluation 
criteria [20]. No growth of the irradiated tumors was defined 
as progression-free.
Acute and late toxicities associated with treatment were 
evaluated with RTOG acute radiation morbidity scoring cri-
teria and RTOG/EORTC late radiation morbidity scoring 
scheme, respectively [5].
Figure 1. Isodose distribution with the anterior and right lateral pro-
ton beams in a hepatocellular carcinoma patient with severe cirrhosis. 
Each isodose line corresponds to 90%, 50%, 30%, and 10% dose levels 
from the inside out, respectively. The critical organs such as the spinal 
cord and the digestive tracts are located entirely outside the irradi-
ated volume due to sharp distal fall-off of the Bragg peak of proton 
beams. 
Abbildung 1. Isodosenverteilung bei anteriorem und lateralem Proto-
nenstrahl bei einem Patienten mit Leberzellkarzinom und schwerer 
Zirrhose. Jede Isodosenlinie von innen nach außen entspricht jeweils 
90%, 50%, 30% und 10%. Die kritischen Organe wie das Rückenmark 
und der Verdauungstrakt liegen wegen des scharfen distalen Abfalls 
der Bragg-Spitze des Protonenstrahls vollständig außerhalb des be-
strahlten Volumens. 
Figures 2a and 2b. Contrast-enhanced CT in arterial phase of a hepatocellular carcinoma patient with severe cirrhosis. a) Just before initiation of 
proton beam therapy. Arrowheads represent position of the hepatic tumor enhanced inhomogeneously. b) 7 months after completion of proton 
beam therapy. The marked reduction of the tumor volume is demonstrated. The intrahepatic high-density region corresponds to an implanted 
metallic fiducial marker. 
Abbildungen 2a und 2b. Kontrastverstärkte CT-Aufnahme in der arteriellen Phase bei einem Patienten mit Leberzellkarzinom und schwerer 
Zirrhose. a) Unmittelbar vor Beginn der Protonentherapie. Die Pfeilspitzen geben die Lage des inhomogen verstärkten Leberzellkarzinoms an. 
b) 7 Monate nach Abschluss der Protonentherapie. Die deutliche Reduktion des Tumorvolumens ist auffällig. Der intrahepatische Bereich erhöhter 
Dichte repräsentiert ein implantiertes metallisches Achsenkreuz. 
Figure 2a – Abbildung 2a                                  Figure 2b – Abbildung 2b Hata M, et al. Proton Beam Therapy for HCC Patients with Severe Cirrhosis
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Statistical Analysis
The actuarial survival rates and the progression- and dis-
ease-free rates were calculated according to the Kaplan-Meier 
method [14]. The prognostic factors for survival were evalu-
ated by the log-rank test [1]. The changes of variables in blood 
tests were examined by the paired t-test. p < 0.05 was consid-
ered statistically significant. All statistical analyses were per-
formed using the statistical software SPSS 11.0J (SPSS Inc., 
Chicago, IL, USA). 
Results 
Tumor Control and Failure Patterns 
Tumor responses were complete response (CR) in nine pa-
tients, partial response (PR) in three, no change (NC) in six, 
and progressive disease (PD) in one. The objective response 
(CR and PR) rate was 63%. The pre- and posttreatment 
CT images of a patient are shown in Figure 2. Consequent-
ly, all but one of irradiated tumors were controlled at the 
median follow-up period of 17 months (range, 3–63 months) 
after treatment; the progression-free rate was 91%. AFP 
values of 14 patients which had shown high levels of 
30–12,539 ng/ml (median 145 ng/ml) beyond the upper 
normal limit of 20 ng/ml before irradiation decreased to 
1–2,141 ng/ml (median 19 ng/ml), to normal range in seven 
patients, after irradiation. 
Ten patients had new hepatic tumors outside the irra-
diated volume 4–30 months after treatment. None had dis-
tant metastases. Of the ten patients with recurrence, two 
(patients # 1 and 2) received second courses of proton beam 
therapy and all recurrent tumors were controlled after reir-
radiation. For the remaining eight patients, radical treatment 
was considered contraindicated due to further deteriorated 
cirrhosis. 
The disease-free rates were 51% at 1 year and 31% at 2 
years (Figure 3). The summaries of all patients divided into 
two groups according to survival time (over or within 1 year) 
are shown in Tables 2 and 3. 
Pre- and Posttreatment Liver Function 
Pre- and posttreatment (1 month after treatment) mean ± 
standard deviation (SD) values of serum albumin and total 
bilirubin, prothrombin activity, and platelets, and those dur-
ing treatment in all patients are summarized in Table 4. Al-
though the mean value of total bilirubin increased and that 
of platelets decreased transiently during treatment, in com-
parison with each pretreatment mean value, there were no sig-
Table 2. Summary of ten hepatocellular carcinoma patients with severe cirrhosis who survived for > 1 year after proton beam therapy. CR: complete 
response; F: female; HBV: hepatitis B virus; HCV: hepatitis C virus; ICH: intracranial hemorrhage; IOIV: inside and outside of the irradiated volume; 
M: male; NED: no evidence of disease; OIV: outside of the irradiated volume; PD: progressive disease; PR: partial response; PS: performance status. 
Tabelle 2. Zusammenfassung der zehn Patienten mit Leberzellkarzinom und schwerer Zirrhose, die > 1 Jahr nach der Protonentherapie überlebten. 
CR: Komplettremission; F: weiblich; HBV: Hepatitis-B-Virus; HCV: Hepatitis-C-Virus; ICH: intrakranielle Blutung; IOIV: innerhalb und außerhalb 
des bestrahlten Bereichs; M: männlich; NED: keine Krankheitszeichen; OIV: außerhalb des bestrahlten Bereichs; PD: fortschreitende Erkrankung; 
PR: Teilremission; PS: Performance-Status. 
Patient   Age (years)/  PS  Etiology  Child-  Number of  Tumor   Total dose  Tumor  Pattern of  Follow-up
#  gender    of cirrhosis  Pugh  tumors  size  (Gy/fractions)  response  failure   (months) 
       score    (mm)       and  status
  1  67/M  1  HCV  10  Solitary  50  84/24  CR  Liver (OIV)  63, dead of trauma
  2  54/M  1  HCV  10  Multiple  25  84/24  CR  Liver (OIV)  56, dead of cancer 
  3  68/M  2  HCV  13  Solitary  35  72.5/19  CR  None  42, dead of liver failure
  4  66/F  0  Alcohol  12  Solitary  30  72/16  CR  Liver (OIV)  37, dead of cancer
  5  63/F  2  HCV  12  Solitary  60  67.5/15  PR  Liver (OIV)  17, dead of cancer
  6  60/F  1  HCV  11  Solitary  40  72/16  CR  Liver (OIV)  57, dead of ICH
  7  52/M  2  HCV  14  Solitary  35  50/10  PD  Liver (IOIV)  19, dead of liver failure
  8  59/M  1  HCV  10  Solitary  35  72/16  CR  Liver (OIV)  32, dead of cancer
  9  66/M  1  HCV  11  Solitary  30  72/16  CR  Liver (OIV)  45, dead of liver failure
10  53/M  1  HCV  12  Solitary  35  50/10  CR  None  33, alive with NED
100
80
60
40
20
0
0  10 20 30 40 50 60  70
Progression-free rate
Disease-free rate
Months
(%)
Figure 3. Progression-free and disease-free rates of 19 hepatocellular 
carcinoma patients with severe cirrhosis treated with proton beams. 
Abbildung 3. Progressionsfreie und krankheitsfreie Raten der Patien-
ten mit Leberzellkarzinom und schwerer Zirrhose, die eine Protonen-
therapie erhielten. Hata M, et al. Proton Beam Therapy for HCC Patients with Severe Cirrhosis
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nificant differences between the pre- and posttreatment mean 
values (Figure 4). 
There was no deterioration in Child-Pugh score, but rath-
er an improvement in 14 patients. 
Survival and Prognostic Factors 
Of 19 patients, six and eight died of cancer 6–56 months and 
liver failure 5–45 months after treatment, respectively. Of 
the remaining five patients, four died of intercurrent diseases 
(n = 2 intracranial hemorrhage, n = 1 trauma, and n = 1 inter-
stitial pneumonitis due to coexisting pulmonary fibrosis) and 
another was alive with no evidence of disease 33 months after 
treatment. The progression-free survival rates were 47% at 
1 year and 42% at 2 years, and the median progression-free 
survival time was 12 months (Figure 5). The overall survival 
rates were 53% and 42% at 1 and 2 years, respectively, and the 
median overall survival time was 17 months (Figure 6). 
Performance status and Child-Pugh score were significant 
prognostic factors for survival (Table 5). 
Toxicity 
Acute reactions of grade 2 or less occurred in six patients (Ta-
ble 6). These toxicities were transient and easily manageable 
and caused no interruption of the treatment. 
No late toxicities associated with the treatment were ob-
served. 
Discussion 
Although the clinical significance of treatment for HCC in 
patients with severe cirrhosis is still unknown, it is currently 
believed that radical treatment for HCC hardly ever contrib-
utes to prolonging survival of the patients. This hypothesis is 
based on the poor prognosis of severe cirrhosis itself. How-
ever, according to some reports the prognosis of severe cir-
rhotic patients has recently improved due to advanced treat-
ments for liver dysfunction or esophageal varices. Planas et 
al. reported that the 1-year survival rate in Child-Pugh class 
C cirrhotic patients was 75% and some patients survived for 
> 5 years [24].
On the other hand, the median survival time of HCC 
patients with Child-Pugh class C cirrhosis treated only with 
supportive care was 3–9 months and all such patients died 
within 3 years [3, 17, 18]. These data suggest that the con-
trol of HCC may result in improvement of prognosis even for 
patients with severe cirrhosis. However, surgical resection is 
generally unfeasible because of the high risk of liver failure or 
bleeding [6, 9]. Aggressive transcatheter arterial chemoembo-
lization (TACE) resulted in the death of 25% of Child-Pugh 
class C cirrhotic patients due to fatal complications includ-
ing gastroduodenal bleeding within 1 month after treatment 
[18]. PEI may be one of the most feasible modalities for small 
Table 3. Summary of nine hepatocellular carcinoma patients with severe cirrhosis who died within 1 year after proton beam therapy. CR: com-
plete response; F: female; HBV: hepatitis B virus; HCV: hepatitis C virus; ICH: intracranial hemorrhage; IP: interstitial pneumonitis; M: male; NC: no 
change; OIV: outside of the irradiated volume; PR: partial response; PS: performance status. 
Tabelle 3. Zusammenfassung der neun Patienten mit Leberzellkarzinom und schwerer Zirrhose, die innerhalb 1 Jahres nach der Protonentherapie 
verstarben. CR: Komplettremission; F: weiblich; HBV: Hepatitis-B-Virus; HCV: Hepatitis-C-Virus; ICH: intrakranielle Blutung; IP: interstitielle Pneu-
monitis; M: männlich; NC: stabile Erkrankung; OIV: außerhalb des bestrahlten Bereichs; PR: Teilremission; PS: Performance-Status. 
Patient   Age (years)/  PS  Etiology  Child-  Number of  Tumor   Total dose  Tumor  Pattern of  Follow-up
#  gender    of cirrhosis  Pugh  tumors  size  (Gy/fractions)  response  failure   (months) 
       score   (mm)       and  status 
11  60/M  2  HCV  12  Multiple  45  77/22  CR  None  4, dead of ICH
12  62/M  1  HBV  13  Solitary  36  84/24  NC  None  5, dead of liver failure
13  57/M  2  HCV  10  Solitary  80  64/15  NC  None  3, dead of IP
14  62/M  1  HCV  12  Multiple  55  72/18  PR  None  10, dead of liver failure
15  62/M  2  HCV  12  Solitary  30  68.8/16  PR  Liver (OIV)  6, dead of cancer
16  58/F  1  Alcohol  12  Solitary  40  68/14  NC  Liver (OIV)  6, dead of cancer
17  69/M  2  HCV  14  Multiple  41  72/16  NC  None  5, dead of liver failure
18  66/M  1  HCV  13  Solitary  57  72/16  NC  None  12, dead of liver failure
19  61/F  2  HCV  12  Multiple  55  66/22  NC  None  6, dead of liver failure
Table 4. Mean values ± SD in serum albumin, total bilirubin, prothrom-
bin activity, and platelets before, during and at 1 month after proton 
beam therapy. SD: standard deviation. 
Tabelle 4. Mittelwert ± SD für Serumalbumin, Gesamtbilirubin, Pro-
thrombinaktivität und Plättchen vor, während und 1 Monat nach der 
Protonentherapie. SD: Standardabweichung. 
Variable Before    During    After
 treatment  treatmenta  treatment
  Mean ± SD
Albumin (g/dl)   2.7 ± 0.3   2.6 ± 0.3   3.0 ± 0.6 
Total bilirubin (mg/dl)   2.8 ± 1.1   3.6 ± 1.5   3.3 ± 1.5 
Prothrombin activity (%)  58.0 ± 13.8  55.1 ± 9.4  56.8 ± 10.0 
Platelets (× 104/µl)   6.9 ± 3.2   4.9 ± 1.5   6.2 ± 2.2 
a mean ± SD of minimum values in albumin, prothrombin activity and platelets and 
of maximum values in total bilirubin for individuals Hata M, et al. Proton Beam Therapy for HCC Patients with Severe Cirrhosis
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HCC with favorable tumor location. Nevertheless, the over-
all survival rates were 40–81% at 1 year and none survived for 
> 2 years. Furthermore, severe and fatal complications such as 
hemoperitoneum, hepatic infarction and abscess, and tumor-
al seeding occurred in some cases, along with uncomfortable 
symptoms such as fever and pain in many cases [7, 10, 15]. Al-
though RFA is also anticipated to be a less invasive modal-
ity, its efficacy has never been demonstrated in patients with 
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Figure 5. Progression-free survival of 19 hepatocellular carcinoma 
patients with severe cirrhosis treated with proton beams.
Abbildung 5. Progressionsfreies Überleben der 19 Patienten mit Le-
berzellkarzinom und schwerer Zirrhose, die eine Protonentherapie 
erhielten.
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Figure 6. Overall survival of 19 hepatocellular carcinoma patients with 
severe cirrhosis treated with proton beams. 
Abbildung 6. Gesamtüberleben der 19 Patienten mit Leberzellkarzi-
nom und schwerer Zirrhose, die eine Protonentherapie erhielten. 
Figures 4a to 4d. Pretreatment (Pre), maximum (Max) or minimum (Min) during treatment, and posttreatment (Post) mean values ± SD of 
a) serum albumin, b) total bilirubin, c) prothrombin activity, and d) platelets. NS: not significant. 
Abbildungen 4a bis 4d. Prätherapeutische (Pre), maximale (Max) oder minimale (Min) Werte während der Behandlung sowie posttherapeutische 
(Post) Mittelwerte ± SD für a) Serumalbumin, b) Gesamtbilirubin, c) Prothrombinaktivität und d) Plättchen. NS: nicht signifikant. 
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severe cirrhosis [29]. To our knowledge, there was no detailed 
report on radiation therapy for HCC patients with severe 
cirrhosis. 
In the current study, proton beam therapy appeared to 
have achieved an improvement in survival for some HCC pa-
tients with severe cirrhosis due to excellent local control and 
reduced toxicity. The overall survival rates of 53% at 1 year 
and 42% at 2 years were better than those of natural course 
[3, 17, 18]. Performance status and Child-Pugh score were sig-
nificant prognostic factors for survival. In particular, five of 
six patients with Child-Pugh scores of 10 and 11 survived for 
> 2 years after treatment. By contrast, eight of nine patients 
who died within 1 year after treatment had Child-Pugh scores 
of ≥ 12. 
All but one patients (95%) had no growth of the irradi-
ated tumor while the tumor sizes were ≥ 30 mm in all patients 
except one and ≥ 50 mm in six patients. The objective response 
rate was 90% in ten patients who survived for > 1 year after 
treatment, and 33% in nine patients who died within 1 year 
after treatment. Usually, the tumor volume of HCC reduces 
gradually over several months, or occasionally over several 
years, on medical imaging after irradiation. All of the irradi-
ated tumors of six NC patients tended to reduce in the final 
imaging studies. Since all NC patients died within 1 year after 
treatment, the intervals between completion of treatment and 
the last evaluation of treatment efficacy may have been insuf-
ficient to achieve an objective response. The dose of 50 Gy in 
ten fractions delivered to the one PD patient was the lowest 
among the present series. This irradiated dose may not have 
been sufficient for tumor control. 
The severe or fatal toxicities which occurred in previous 
studies with other treatment modalities were not observed at 
all in this series. 
Conclusion 
Proton beam therapy for HCC patients with severe cirrhosis 
was tolerable. It may improve survival for the patients with 
relatively good general condition and liver function. 
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